Division of Alzheimer Neurobiology, Karolinska Institutet,Karolinska University Hospital Huddinge, Novum 5th floor, SE-141 86 Stockholm, Sweden.
Neurodegener Dis. 2010;7(1-3):136-8. doi: 10.1159/000289223. Epub 2010 Mar 3.
Amyloid imaging has provided evidence for early detection of amyloid (Abeta) load in prodromal Alzheimer's disease (AD). Several amyloid tracers have been developed for studies with positron emission tomography (PET). Early detection of at-risk subjects will be important in the future for a successful treatment of AD. The high Abeta load in the brain measured by PET in patients with mild cognitive impairment that later will convert to AD suggests early, significant, ongoing pathological processes prior to cognitive impairment. PET Abeta imaging will also be used for discrimination of AD from other dementia disorders, as well for the evaluation of anti-Abeta drugs.
淀粉样蛋白成像为前驱期阿尔茨海默病(AD)的淀粉样蛋白(Abeta)负荷的早期检测提供了证据。已经开发了几种淀粉样蛋白示踪剂用于正电子发射断层扫描(PET)研究。在未来,对 AD 进行成功治疗的关键是早期发现高危人群。在轻度认知障碍患者中,通过 PET 测量到的大脑中 Abeta 负荷较高,这些患者以后会转化为 AD,这表明在认知障碍之前存在早期、显著且持续的病理过程。PET Abeta 成像也将用于 AD 与其他痴呆症的鉴别,以及抗 Abeta 药物的评估。